These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33418362)

  • 1. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Shekotikhina M; Vinberg M; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    J Affect Disord; 2021 Mar; 282():160-164. PubMed ID: 33418362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
    Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
    [No Abstract]   [Full Text] [Related]  

  • 4. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
    Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
    J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
    van Schalkwyk GI; Wilkinson ST; Davidson L; Silverman WK; Sanacora G
    J Affect Disord; 2018 Feb; 227():11-16. PubMed ID: 29045915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do the dissociative side effects of ketamine mediate its antidepressant effects?
    Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
    J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
    Williamson D; Turkoz I; Wajs E; Singh JB; Borentain S; Drevets WC
    Int J Neuropsychopharmacol; 2023 Mar; 26(3):198-206. PubMed ID: 36525338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders.
    Castle C; Gray A; Neehoff S; Glue P
    J Psychopharmacol; 2017 Oct; 31(10):1306-1311. PubMed ID: 28922961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
    Mello RP; Echegaray MVF; Jesus-Nunes AP; Leal GC; Magnavita GM; Vieira F; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Souza-Marques B; Bandeira ID; Santos-Lima C; Marback RF; Correia-Melo FS; Lacerda ALT; Quarantini LC
    J Psychiatr Res; 2021 Jun; 138():576-583. PubMed ID: 33991996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Zarate CA; Park LT
    J Affect Disord; 2020 Feb; 263():568-575. PubMed ID: 31791675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
    Mathai DS; Meyer MJ; Storch EA; Kosten TR
    J Affect Disord; 2020 Mar; 264():123-129. PubMed ID: 32056741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide ('laughing gas')-induced anomalous states.
    Piazza GG; Iskandar G; Hennessy V; Zhao H; Walsh K; McDonnell J; Terhune DB; Das RK; Kamboj SK
    Psychopharmacology (Berl); 2022 Jul; 239(7):2317-2329. PubMed ID: 35348804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Nasri F; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    Expert Opin Drug Saf; 2020 Aug; 19(8):1031-1040. PubMed ID: 32539491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Ning YP
    J Affect Disord; 2023 Aug; 334():145-151. PubMed ID: 37160235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
    Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
    Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.
    Cullen KR; Amatya P; Roback MG; Albott CS; Westlund Schreiner M; Ren Y; Eberly LE; Carstedt P; Samikoglu A; Gunlicks-Stoessel M; Reigstad K; Horek N; Tye S; Lim KO; Klimes-Dougan B
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):437-444. PubMed ID: 30004254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.